WuXi AppTec(SH:603259) Xin Lang Cai Jing·2026-02-05 02:01Group 1 - The core viewpoint of the articles highlights the positive performance of the Hong Kong pharmaceutical sector, with the CSI Hong Kong Stock Connect Pharmaceutical and Health Index rising by 0.32% as of February 5, 2026, and several key stocks such as Yino Pharma-B and WuXi AppTec showing significant gains [1] - The National Medical Products Administration is set to strongly support the innovation and development of the biomanufacturing industry during the 14th Five-Year Plan period, indicating a favorable policy environment for the pharmaceutical sector [1] - Donghai Securities predicts that 2025 will be a year of accelerated profitability for domestic innovative drugs, with leading companies like Innovent Biologics and Rongchang Biopharmaceuticals expected to achieve full-year profitability for the first time, driven by rapid commercialization and business development collaborations [1] Group 2 - The CSI Hong Kong Stock Connect Pharmaceutical and Health Index comprises 50 liquid and large-cap healthcare companies, reflecting the overall performance of the pharmaceutical sector within the Stock Connect framework [1] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi Biologics, BeiGene, and others, accounting for 64.57% of the total index weight, indicating a concentration of investment in these leading firms [2] - The Hong Kong pharmaceutical ETF closely tracks the CSI Hong Kong Stock Connect Pharmaceutical and Health Index, providing investors with a means to gain exposure to the sector [2]